MF
BEAM icon

Manchester Financial’s Beam Therapeutics BEAM Stock Holding History

Manchester Financial’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-110
Closed -$9K – 137
2021
Q1 		$9K Hold
110
– – ﹤0.01% 439
2020
Q4 		$9K Hold
110
– – 0.01% 374
2020
Q3 		$3K Buy
+110
New +$2.73K ﹤0.01% 446

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Manchester Financial's BEAM Position: Q2 2021 in Review

Manchester Financial sold out of Beam Therapeutics (BEAM) in Q2 2021, closing a stake of 110 shares — an estimated $9K sold.

Manchester Financial first reported a position in BEAM in Q3 2020 and held it in 3 quarters. The position peaked at $9K in Q1 2021. 231 funds tracked by Wall St. Rank hold BEAM as of Q2 2021.

  • Manchester Financial reported no remaining Beam Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Manchester Financial sold 110 Beam Therapeutics shares in Q2 2021, an estimated $9K.
  • Manchester Financial first reported a position in Beam Therapeutics in Q3 2020 and held it in 3 quarters.
  • Manchester Financial's Beam Therapeutics position peaked at $9K in Q1 2021.
  • 231 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2021.

Based on Manchester Financial's 13F filing for Q2 2021, filed 21 Jul 2021.